believe study of bimagrumab + semaglutide Weight loss and muscle loss. The facts. GLP-1 drugs like and tirzepatide produce impressive weight loss — but a consistent and underappreciated finding across trials is that a meaningful proportion A phase 2 clinical trial

The medication continues to suppress appetite, and the health benefits, lower blood pressure, improved glucose control, reduced inflammation, persist as long as treatment continues

Blood work at this stage frequently reveals improvements beyond weight

LDL particles must penetrate the arterial wall, become oxidized, and trigger an inflammatory response to contribute to plaque formation

These adjustments arent glamorous, but they create a hormonal environment that supports fat loss rather than fighting it

Across multiple SUSTAIN trials, patients treated with semaglutide 0.5 mg or 1.0 mg weekly demonstrated statistically significant reductions in total cholesterol and LDL-C compared to placebo and several active comparators